Pfizer: the pipeline is worth more than the balance sheet discount
Three launches land inside eighteen months with limited competition on two of them. The market still prices this as a levered generics business.
Unlock the full report
The locked call and the disclosures stay visible. The research body unlocks with purchase or subscription.
Discussion · 6
Respectfully, I think this overstates it. The capital intensity point is the one I keep coming back to. Would you underwrite this without the catalyst date?
That is where I would push back. I would size it smaller at a higher entry rather than skip it, because the asymmetry degrades gradually rather than cliff-edges.
I came in sceptical. The regulatory ceiling being quantified changes the model, not just the headline. Curious whether you would still size it the same at a higher entry.
I have been waiting for someone to make this argument. The exclusivity window is the part the market keeps mispricing. Would you underwrite this without the catalyst date?
This lines up with what I saw in the filings. The exclusivity window is the part the market keeps mispricing. What would you need to see to add rather than hold?
This is the second-order point everyone skips. The channel data is what makes this hard to dismiss. What does the bear actually have to be right about?